Last reviewed · How we verify
Dostarlimab in Combination Antiretroviral Therapy
Dostarlimab in Combination Antiretroviral Therapy is a Small molecule drug developed by Imperial College London. It is currently in Phase 1 development.
At a glance
| Generic name | Dostarlimab in Combination Antiretroviral Therapy |
|---|---|
| Sponsor | Imperial College London |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dostarlimab in Combination Antiretroviral Therapy CI brief — competitive landscape report
- Dostarlimab in Combination Antiretroviral Therapy updates RSS · CI watch RSS
- Imperial College London portfolio CI
Frequently asked questions about Dostarlimab in Combination Antiretroviral Therapy
What is Dostarlimab in Combination Antiretroviral Therapy?
Dostarlimab in Combination Antiretroviral Therapy is a Small molecule drug developed by Imperial College London.
Who makes Dostarlimab in Combination Antiretroviral Therapy?
Dostarlimab in Combination Antiretroviral Therapy is developed by Imperial College London (see full Imperial College London pipeline at /company/imperial-college-london).
What development phase is Dostarlimab in Combination Antiretroviral Therapy in?
Dostarlimab in Combination Antiretroviral Therapy is in Phase 1.